Have any questions? [email protected] +86-21-58998590
Structure search

OTS193320


CAS No. : 2093401-33-1

2093401-33-1
Price and Availability of CAS No. : 2093401-33-1
Size Price Stock
5mg $380 In-stock
10mg $620 In-stock
25mg $1250 In-stock
50 mg Get quote
100 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-122182
M.Wt: 536.02
Formula: C28H30ClN5O4
Purity: >98 %
Solubility: DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)
Introduction of 2093401-33-1 :

OTS193320, a imidazo[1,2-a]pyridine compound, is a SUV39H2 methyltransferase activity inhibitor. OTS193320 decreases global histone H3 lysine 9 tri-methylation levels in breast cancer cells and triggers apoptotic cell death. Combination of OTS193320 with Doxorubicin (DOX; HY-15142A) results in reduction of γ-H2AX levels as well as cancer cell viability compared to a single agent OTS193320 or DOX[1]. In Vitro:OTS193320 (0.125-0.5 μM; 24 hours) has growth inhibitory effect on breast cancer cell lines. OTS193320 exhibits a high inhibitory effect against SUV39H2 enzymatic activity (IC50=22.2 nM) and a growth suppressive effect of SUV39H2-positive A549 lung cancer cells (IC50=0.38 μM)[1].
OTS193320 (0.5 μM; 48 hours) induces apoptosis in breast cancer cells[1].
OTS193320 (0.125-0.5 μM; 24 hours) causes attenuation of H3K9me3 levels in a dose-dependent manner[1].
OTS193320 sensitizes breast cancer cells to doxorubicin via attenuation of γ-H2AX. Combination of OTS193320 and doxorubicin (DOX) significantly attenuates cancer cell viability in vitro, compared to single agent treatment of either drug[1].

Your information is safe with us.